Company Filing History:
Years Active: 2015-2021
Title: Rita Slaaby: Innovator in Diabetes and Obesity Treatment
Introduction
Rita Slaaby is a prominent inventor based in Lyngby, Denmark. She has made significant contributions to the field of pharmaceuticals, particularly in the development of insulin analogues and treatments for diabetes, obesity, and cardiovascular diseases. With a total of 2 patents, her work has the potential to impact the lives of many individuals suffering from these conditions.
Latest Patents
One of her latest patents is titled "Acylated insulin analogues and uses thereof." This invention relates to novel insulin analogues and derivatives, specifically acylated insulin analogues, and their pharmaceutical applications in treating or preventing medical conditions associated with diabetes, obesity, and cardiovascular diseases. Another significant patent is "Process for preparing FGF21 with low degree of O-glycosylation." This patent describes how the expression of FGF21 in an apmt2 knockout strain significantly reduces O-glycosylation without decreasing the expression level. Additionally, it highlights that expression in a mkc7 knockout strain can decrease the degradation of FGF21 and its analogues, with specific point mutations at positions R17 and R36 further enhancing stability when expressed in yeast.
Career Highlights
Rita Slaaby is currently employed at Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care and other chronic conditions. Her work at Novo Nordisk has allowed her to focus on innovative solutions that address critical health issues.
Collaborations
Throughout her career, Rita has collaborated with notable colleagues, including Inger Lautrup-Larsen and Grith Skytte Olsen. These collaborations have fostered a productive environment for research and development in the pharmaceutical field.
Conclusion
Rita Slaaby's contributions to the development of insulin analogues and treatments for diabetes and obesity highlight her role as an influential inventor in the pharmaceutical industry. Her innovative patents and work at Novo Nordisk A/S continue to pave the way for advancements in medical treatments.